The amyloid hypothesis of Alzheimer's disease suggests that synaptic degeneration and pathology is caused by the accumulation of amyloid-b (Ab) peptides derived from the amyloid precursor protein (APP). Subsequently, soluble Ab oligomers cause the loss of synaptic proteins from neurons, a histopathological feature of Alzheimer's disease that correlates with the degree of dementia. In this study, the production of toxic forms of Ab was examined in vitro using 7PA2 cells stably transfected with human APP. We show that conditioned media from 7PA2 cells containing Ab oligomers caused synapse degeneration as measured by the loss of synaptic proteins, including synaptophysin and cysteine-string protein, from cultured neurons. Critically, conditioned media from 7PA2 cells treated with valproic acid (2-propylpentanoic acid (VPA)) or propylisopropylacetic acid (PIA) did not cause synapse damage. Treatment with VPA or PIA did not significantly affect total Ab 42 concentrations; rather these drugs selectively reduced the concentrations of Ab 42 oligomers in conditioned media. In contrast, treatment significantly increased the concentrations of Ab 42 monomers in conditioned media. VPA or PIA treatment reduced the concentrations of APP within lipid rafts, membrane compartments associated with Ab production. These effects of VPA and PIA were reversed by the addition of platelet-activating factor, a bioactive phospholipid produced following activation of phospholipase A 2 , an enzyme sensitive to VPA and PIA. Collectively these data suggest that VPA and PIA reduce Ab oligomers through inhibition of phospholipase A 2 and suggest a novel therapeutic approach to Alzheimer's treatment.
Introduction
Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia resulting from synaptic failure (Selkoe, 2002) . The amyloid hypothesis maintains that the accumulation of neurotoxic amyloid-b (Ab) peptides following the proteolytic cleavage of the amyloid precursor protein (APP) (Hardy, 2006) causes neurodegeneration (Lambert et al., 1998) . The production of Ab is a key therapeutic target that can be investigated in cells transfected with the human APP gene; which metabolise APP to toxic forms of Ab (Walsh et al., 2005) . 7PA2 cells are Chinese hamster ovary (CHO) cells transfected with human APP that produce Ab that are of similar size and potency to soluble Ab derived from AD patients (Podlisny et al., 1995) . Ab peptides in brains of AD patients are found in a mixture of complex physical forms. Not all forms of Ab have equal biological significance; toxicity is dependent upon the state of Ab, whether that is the length of peptide, state of aggregation, homogeneity of aggregates or specific Ab conformations. Thus, there exist disease-relevant conformations of Ab, while other conformations are less toxic or biologically inert (Yang et al., 2017) . The identity of "toxic Ab" remains highly controversial; Ab oligomers of similar size demonstrate dissimilar toxicity (Ladiwala et al., 2012) and consequently it is difficult to ascribe biological function to specific Ab conformations as identified in biophysical methods. Therefore drug treatments could reduce non-toxic forms of Ab without affecting the biologically active forms of Ab. To overcome this problem the effects of Ab released from treated 7PA2 cells was examined.
Extensive synapse degeneration is observed in Alzheimer's patients (Heinonen et al., 1995) and the reductions in synaptic proteins correlate closely with the degree of dementia in AD (Hamos et al., 1989; Terry et al., 1991) . Small, soluble Ab oligomers are thought to be the main form of Ab that causes synapse degeneration (Yang et al., 2017) . For these reasons the effects of conditioned media (CM) from 7PA2 cells upon synapses in cultured neurons was tested. Synaptic density was determined by quantifying the amounts of synaptophysin and cysteine string protein (CSP) using enzyme-linked immunoassays (ELISA). The amounts of synaptophysin has been used to access synaptic density in the brain (Reddy et al., 2005; Counts et al., 2006) and in cultured neurons (Williams and Bate, 2016) . Although the processing of APP is affected by phospholipase A 2 (PLA 2 ) inhibitors (Emmerling et al., 1993) , conventional cPLA 2 inhibitors do not readily cross the blood-brain barrier and their use in AD is limited. Several reports demonstrated that valproic acid (2-propylpentanoic acid or VPA), a short branched-chain fatty acid acts like a PLA 2 inhibitor (Williams and Bate, 2016; Bosetti et al., 2003) . Furthermore, although VPA has also been reported to reduce Ab production (Qing et al., 2008a; Su et al., 2004) it was not clear which forms of Ab were reduced. Here we report that the treatment of 7PA2 cells with VPA and its congener propylisopropylacetic acid (PIA), but not decanoic acid (DA), reduced the production of toxic forms of Ab. These drugs had only a small effect upon concentrations of Ab; rather they caused a switching from the production of toxic Ab oligomers to non-toxic Ab monomers.
Materials and methods

7PA2 cells
CHO cells stably transfected with cDNA encoding human APP 751 (referred to as 7PA2 cells) (Podlisny et al., 1995) were provided by Professor E Koo (University of California). These were cultured in neurobasal medium supplemented with B27 components (Invitrogen) in the presence of compounds for 72 h. CM was collected, filtered, desalted and passed through a 50 kDa filter (VivaspinSartorious). CM from CHO cells (CHO-CM) were used as controls. To determine cell viability thiazolyl blue tetrazolium bromide (Sigma) was added to cells at a final concentration of 50 mM for 3 h at 37 C.
The medium was removed, the formazan product solubilized in 200 ml of dimethyl sulfoxide, transferred to an immunoassay plate and absorbance read at 595 nm. Cell survival was calculated with reference to untreated cells (100% survival). Cell extracts were collected from treated cells washed 3 times with ice cold PBS and homogenised in extraction buffer (containing 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.2% SDS and mixed protease inhibitors (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, Aprotinin, Leupeptin, Bestatin, Pepstatin A and E-46) (Sigma)) at 10 6 cells/ml. Cellular debris was removed by centrifugation (20 min as 16000 Â g) and the supernatant collected. 7PA2-CM containing Ab monomers were prepared by filtration of 2 mls 7PA2-CM through a 10 kDa filter (Sartorius). Oligomer preparations were the 7PA2-CM retained by the 10 kDa filter diluted back to the original volume (2 mls). For immunoblot analysis, 7PA2-CM/ monomer or oligomer preparations were concentrated from 2000
to 100 mls using a 3 kDa filter (Sartorius). 10 ml of sample were mixed with an equal volume of in 0.5% NP-40, 5 mM CHAPS, 50 mM Tris, pH 7.4 and separated by electrophoresis on 15% polyacrylamide gels. Proteins were transferred onto a Hybond-P polyvinylidene fluoride membrane by semi-dry blotting and blocked using 10% milk powder. Ab was detected by incubation with mAb 6E10 (Covance), biotinylated anti-mouse IgG, extravidinperoxidase and enhanced chemiluminescence. Soluble brain extracts (containing peptides between 3 and 50 kDa) were prepared from brain tissue derived from Alzheimer's patients as described (Williams and Bate, 2016) .
Brain extracts
Samples of temporal lobes from 3 patients with a pathologically-confirmed, clinical diagnosis of Alzheimer's diseasewas supplied by Asterand. Soluble extracts were prepared using methodology as described (Shankar et al., 2008) . Briefly, pieces of brain tissue of approximately 100 mg were added to tubes containing lysing matrix D beads (Q-Bio). Ice cold 20 mM Tris, pH 7.4 containing 150 mM NaCl was added to an equivalent of 100 mg brain tissue/ml, tubes were shaken for 10 min (Disruptor genie, Scientific Instruments). This process was performed 3 times before tubes were centrifuged at 16,000 Â g for 10 min to remove particulate matter. Soluble material was prepared by passage through a 50 kDa filter (Sartorius) (16,000 Â g for 30 min). The remaining material was desalted (3 kDa filter (Sartorius)) the retained material collected (preparation contains molecules with molecular weights between 3 and 50 kDa). Monomers were prepared by passage through a 10 kDa filter (Sartorius) and oligomers were collected from the material that was retained (10e50 kDa). Preparations were stored at À80 C. For cell experiments preparations were diluted in neurobasal medium containing B27 components. For immunoblots, preparations were separated by electrophoresis and visualised as outlined above.
Immunodepletions
To deplete preparations of Ab they were incubated with 1 mg/ml mAb 4G8 (reactive with amino acids 17e24 of Ab, Covance) or 1 mg/ ml mAb LN27 (reactive with amino acids 45 to 53 of APP, (mockdepletion)) and incubated on rollers for 2 h. Protein G microbeads were added (10 ml/ml) (Sigma) for 30 min and protein G boundantibody complexes removed by centrifugation (1000 Â g for 5 min) and passed through a 0.2 mm filter.
Isolation of detergent-resistant membranes (DRMs (lipid rafts))
These membrane domains were isolated by their insolubility in non-ionic detergents as described (London and Brown, 2000) . Briefly, cells were homogenised in an ice-cold buffer containing 1% Triton X-100, 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM EDTA and mixed protease inhibitors. Nuclei and large fragments were removed by centrifugation (300 Â g for 5 min at 4 C). The post nuclear supernatant was incubated on ice (4 C) for 1 h (shaken at 10 min intervals) and centrifuged (16,000 Â g for 20 min at 4 C). The supernatant was reserved as the detergent-soluble membrane (DSM) while the insoluble pellet was homogenised in an extraction buffer containing 10 mM Tris-HCL, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS and mixed protease inhibitors at 10 6 cells/ml, centrifuged (10 min at 16,000 Â g) and the soluble material was reserved as the DRM fraction.
Western Blotting
Samples were mixed with Laemmli buffer containing b-mercaptoethanol, heated to 95 C for 5 min and proteins were separated by electrophoresis on 15% polyacrylamide gels. Proteins were transferred onto a Hybond-P polyvinylidene fluoride membrane by semi-dry blotting. Membranes were blocked using 10% milk powder; APP was detected with rabbit polyclonal anti-APP (Sigma), caveolin with rabbit polyclonal anti-caveolin (Upstate) and platelet-activating factor (PAF) receptor with rabbit polyclonal anti-PAF receptor (Cayman chemicals). These were visualised using a combination of biotinylated anti-mouse/goat/rat/rabbit IgG (Sigma), extravidin-peroxidase and enhanced chemiluminescence.
Primary neuronal cultures
Primary cortical neurons were prepared from the brains of mouse embryos (day 15.5) after mechanical dissociation. Neurons were plated at 5 Â 10 5 cells/well in 48 well plates in Hams F12
containing 5% foetal calf serum for 2 h. Cultures were shaken (600 r.p.m for 5 min) and non-adherent cells removed by 2 washes in phosphate buffered saline (PBS). Neurons were subsequently grown in neurobasal medium supplemented with B27 components (Invitrogen) and 5 nM nerve growth factor for 10 days. Immunohistochemistry showed that greater than 90% of cells were neurofilament positive. Neurons were incubated with 7PA2-CM/CHO-CM for 24 h as described (Bate et al., 2010) . Neurons were washed twice in ice-cold PBS and homogenised in a buffer containing 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.2% SDS containing mixed protease and phosphatase inhibitors (as above) at 10 6 cells/ ml. Nuclei and cell debris was removed by low speed centrifugation (300 Â g for 5 min). All experiments were performed in accordance with European regulations (European Community Council Directive, 1986 , 56/609/EEC) and approved by the local authority veterinary service/ethical committee.
Synaptophysin ELISA
Maxisorb immunoplates (Nunc) were coated with antisynaptophysin mouse monoclonal antibody MAB368 (Millipore) and bound synaptophysin was detected using rabbit polyclonal anti-synaptophysin (Abcam) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate solution (Sigma). Absorbance was measured on a microplate reader at 405 nm. Samples were expressed as "units synaptophysin" where 100 units were defined as the amount of synaptophysin in 10 6 control neurons.
CSP ELISA
Maxisorb immunoplates were coated with a monoclonal antibody (mAb) to CSP (Santa Cruz). Samples were added and bound CSP was detected using rabbit polyclonal anti-CSP (Santa Cruz) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol phosphate solution. Absorbance was measured at 405 nm. Samples were expressed as "units CSP" where 100 units were defined as the amount of CSP in 10 6 control neurons.
Sample preparation
To detach Ab 42 from membrane components that blocked specific epitopes samples (300 ml) were mixed with 700 ml of propan-2-ol and sonicated. Proteins were precipitated by adding 250 mls 100%w/v trichloroacetic acid, incubating on ice for 30 min and centrifugation (16,000 Â g for 10 min at 4 C). The pellet was washed twice with ice cold acetone, dried, suspended in a buffer containing 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA and 0.2% SDS and sonicated.
Ab 42 ELISA
Nunc Maxisorb immunoplates were coated with mAb 4G8 (epitope 17e24) (Covance) in carbonate buffer overnight. Plates were blocked with 5% milk powder in PBS-tween and samples were applied. The detection antibody was an Ab 42 selective rabbit mAb BA3-9 (Covance) followed by biotinylated anti-rabbit IgG and extravidin alkaline phosphatase (Sigma). Total Ab was visualised by addition of 1 ng/ml 4-nitrophenol phosphate solution and optical density was read in a spectrophotometer at 405 nm.
Ab 40 ELISA
Maxisorb immunoplates were coated with mAb 4G8 (epitope 17e24) and blocked with 5% milk powder in PBS-tween. Samples were applied and Ab 40 was detected with rabbit polyclonal PC-149 (Merck) followed by biotinylated anti-rabbit IgG and extravidin alkaline phosphatase. Total Ab was visualised by addition of 1 mg/ ml 4-nitrophenol phosphate and optical density was read in a spectrophotometer at 405 nm.
APP ELISA
Maxisorb immunoplates were coated with 1 mg/ml mouse mAb anti-APP (Clone 1G6 -epitope 573e596 (Biolegend)) and blocked with 5% milk powder in PBS-tween. Samples were applied and bound APP was detected using rabbit polyclonal raised against the N-terminal of APP (epitope 40 to 60 (Sigma)) followed by antirabbit IgG conjugated to alkaline phosphatase (Sigma) and 1 mg/ ml 4-nitrophenol phosphate. Absorbance was measured on a microplate reader at 405 nm and results were calculated by comparison to serial dilutions of cell extracts from control cells.
Cholesterol measurement
The concentrations of cholesterol in samples were measured using the Amplex Red cholesterol assay kit (Life Technologies) (Robinet et al., 2010) . Briefly, control and treated cells were washed (400 Â g, 10 min) and lipids extracted by homogenization in hexane:isopropanol (3:2, v/v) 10 min in a cell disruptor (Disruptor genie, Scientific Instruments). Samples were centrifuged (10,000 Â g, 1 min), supernatants collected and dried under nitrogen. Lipids were dissolved in 500 ml isopropanol:NP40 (9:1 v/v) and sonicated in a waterbath (30 min). Samples were pre-treated with catalase before the enzyme cocktail of the Amplex-red kit was added (0.1 M potassium phosphate buffer, pH 7.4; 0.25 M NaCl, 5 mM cholic acid, 0.1% Triton X-100, cholesterol oxidase, horseradish peroxidase, (±cholesterol esterase) and 0.4 mM 10-acetyl-3,7-dihydroxyphenoxazine) and incubated at 37 C for 30 min. Cholesterol is oxidised by cholesterol oxidase to yield hydrogen peroxide and ketones. The hydrogen peroxide reacts with 10-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red reagent) to produce highly fluorescent resorufin, which is measured by excitation at 530 nm and emission detection at 590 nm. Each experiment contained cholesterol standards and solvent only controls. Cholesterol concentrations of samples were calculated by reference to the cholesterol standards.
Compounds
VPA and DA were obtained from Sigma. PIA was obtained from Ukrogsyntez Ltd. Stock solutions were dissolved in ethanol or dimethyl sulphoxide and diluted in medium to obtain final working concentrations. Vehicle controls consisted of equal dilutions of ethanol or di-methyl sulphoxide.
Statistical analysis
Comparison of treatment effects was carried out using Student's paired t-tests. Error values are reported as standard deviations (SD) and significance was determined where P < 0.01. Bivariate analysis using Pearson's coefficient (IBM SPSS statistics 20) were used to examine correlations between data sets.
Results
7PA2 cells released toxic Ab
Neurons incubated with CM from 7PA2 cells contained significantly less synaptophysin than did neurons incubated with CM from CHO cells (Fig. 1A) Previous studies showed that the loss of synaptophysin was accompanied by the loss of other synaptic proteins including, CSP, vesicle-associated membrane protein-1 and synapsin-1 (Bate et al., 2010) indicative of synapse damage. To ascertain whether Ab was the active component in 7PA2-CM it was removed immunoprecipitation with mAb 4G8 (reactive with Ab) (Fig. 1B) . Immunodepletion with 4G8 reduced the concentrations of Ab 42 (0.04 nM ± 0.04 compared with 2.21 nM ± 0.3, n ¼ 9, P < 0.01) and Ab 40 (0.23 nM ± 0.21 compared with 7.42 ± 0.6 nM, n ¼ 9, P < 0.01) in 7PA2-CM. Mock-depletions did not significantly affect the concentration of Ab 40 (6.95 nM ± 0.81 compared with 7.42 nM ± 0.6, n ¼ 9, P ¼ 0.2) or Ab 42 (2.03 nM ± 0.21 compared with 2.21 ± 0.3 nM, n ¼ 9, P ¼ 0.21). We then assessed the role of CM on neurons. These immunoprecipitation studies demonstrate that synaptophysin loss was mediated by Ab since the change caused by 7PA2-CM was lost following immunoprecipitation with mAb 4G8 (reactive with Ab) but was unaffected by mock-depletion (Fig. 1A) . Synaptophysin loss from neurons was also monitored following exposure to soluble brain extracts derived from an Alzheimer's patient which was also Ab-dependent (Williams and Bate, 2016 ). An immunoblot showed that soluble brain extract also contained Ab monomers, dimers and trimers (Fig. 1C) . 7PA2-CM and brain extracts containing similar concentrations of Ab 42 caused dose-dependent reductions in synaptophysin and CSP from neurons indicative of synapse damage ( Fig. 1D and E) .
VPA reduced toxic Ab in CM
Since VPA has been reported to reduce Ab production in a transgenic murine model of AD (Qing et al., 2008b ) the effects of VPA and 2 related molecules (PIA and DA (Chang et al., 2013) ) on Ab production in 7PA2 cells was studied. 7PA2 cells were treated with 10 mM VPA, PIA or DA for 3 days. The survival or growth of 7PA2 cells, as measured by thiazolyl blue tetrazolium, was not affected by treatment with 10 mM VPA (99% cell survival ± 4 compared with 100% ± 6, n ¼ 9, P ¼ 0.85), 10 mM PIA (99% cell survival ± 4 compared with 100% ± 6, n ¼ 9, P ¼ 0.75) or 10 mM DA (101% cell survival ± 5 compared with 100% ± 6, n ¼ 9, P ¼ 0.64). Critically, CM from 7PA2 cells treated with VPA or PIA did not cause the loss of synaptophysin ( Fig. 2A) or CSP (Fig. 2B ) from neurons, whereas the CM from cells treated with 10 mM DA caused as much synapse damage as did CM from control 7PA2 cells. This effect of VPA and PIA was dose-dependent (Fig. 2C) (Walsh et al., 2002 (Walsh et al., , 2005 . Treatment with 10 mM VPA did not significantly reduce the concentrations of Ab 42 (2.43 nM ± 0.39 compared with 2.62 nM ± 0.32, n ¼ 6, P ¼ 0.4) or Ab 40 (8 nM ± 1.5 compared with 8.4 ± 1.2, n ¼ 6, P ¼ 0.72) found in CM when compared to control cells. Similarly, there were no significant differences between the concentrations of Ab 42 (2.35 nM ± 0.3 compared with 2.62 nM ± 0.32, n ¼ 6, P ¼ 0.28) or Ab 40 (8.4 nM ± 1.2 compared with 8.4 ± 1.2, n ¼ 6, P ¼ 0.94) found in CM from cells treated with 10 mM PIA and controls. The surprising observation that CM from VPA and PIA-treated 7PA2 cells contained appreciable concentrations of Ab 42 but did not cause synapse damage could be explained by observations that Ab 42 exists in both disease-relevant forms and non-relevant pools (Benilova et al., 2012) . For example, synapse damage is thought to be caused by the soluble Ab 42 oligomers rather than Ab monomers (Walsh et al., 2002; Shankar et al., 2007) .
The hypothesis that the toxicity of 7PA2-CM was dependent upon the concentration of Ab oligomers was tested by separating 7PA2-CM into monomers and oligomers by passage through a 10 kDa filter. Immunoblots showed that the retained material contained Ab oligomers with no Ab monomers (Fig. 3A) . Treatment with VPA or PIA, but not DA, reduced the concentrations of Ab 42 oligomers in a dose-dependent manner (Fig. 3B) . Concentrations of Ab 40 oligomers were low and there were no significant differences between CM from control cells and cells treated with 10 mM VPA (0.26 nM ± 0.12 compared with 0.19 ± 0.12, n ¼ 6, P ¼ 0.49) or 10 mM PIA (0.26 nM ± 0.12 compared with 0.19 ± 0.12, n ¼ 6, P ¼ 0.46). There were significant inverse correlations between the concentrations of Ab 42 oligomers in CM from VPA or PIA-treated cells (1.25e10 mM) and the amounts of synaptophysin (Fig. 3C) or CSP (Fig. 3D ) in neurons incubated with these CM.
VPA increased concentrations of Ab 42 monomers
Immunoblots showed that 7PA2-CM that passed through the 10 kDa filter contained a single band that migrated as a monomer (Fig. 4A) . Treatment of these cells with VPA or PIA caused a dosedependent increase in Ab 42 monomers (Fig. 4B) . These compounds did not alter the concentrations of Ab 40 monomers; there were no significant differences between CM from control cells and cells treated with 10 mM VPA (7.9 nM ± 0.95 compared with 7.56 ± 0.82, n ¼ 6, P ¼ 0.49) or 10 mM PIA (0.79 nM ± 0.95 compared with 7.42 ± 0.58, n ¼ 6, P ¼ 0.46). There were significant inverse correlations between the concentrations of Ab 42 oligomers and monomers in CM from cells treated with VPA (1.25e10 mM), Pearson's coefficient ¼ -0.92, P < 0.01, or with PIA (1.25e10 mM), Pearson's coefficient ¼ -0.94 P < 0.01 (Fig. 4C) .
VPA did not disrupt Ab 42 oligomers
The loss of Ab oligomers and corresponding increase in Ab monomers following treatment with VPA or PIA suggested that these compounds may interact directly with Ab oligomers causing their dissociation into monomers. To test this hypothesis Ab oligomer preparations (containing 10 nM Ab 42 ) were incubated directly with 10 nM VPA or 10 nM PIA at 37 C. After 3 days preparations were centrifuged through a 10 kDa filter to isolate Ab 42 monomers. Monomeric forms of Ab 42 were not detected in preparations incubated with control medium, VPA or PIA. In addition, there was no significant reductions in the concentrations of Ab 42 oligomers between control preparations and preparations containing VPA (9.77 nM ± 0.25 compared with 9.69 nM ± 0.21, n ¼ 6, P ¼ 0.62) or PIA (9.77 nM ± 0.25 compared with 9.81 nM ± 0.23, n ¼ 6, P ¼ 0.78).
The possibility that VPA/PIA affected the release of Ab from cells was examined by measuring Ab 42 in cell extracts. The concentrations of Ab 42 oligomers in 7PA2 cells were significantly reduced by treatment with 10 mM VPA or with 10 mM PIA, but not by treatment with 10 mM DA (Table 1) . Treatment with VPA and PIA also increased the amounts of cell-associated Ab 42 monomers.
CM from VPA-treated 7PA2 cells reduced Ab-induced synapse damage
Reports that Ab monomers are neuroprotective (Giuffrida et al., 2009) suggested that the Ab 42 monomers released from treated cells may protect neurons. This hypothesis was tested by mixing CM from 7PA2 cells treated with VPA, PIA or DA with Ab derived from a soluble brain extract containing 2 nM Ab 42 and adding the mixture to neurons. CM from 7PA2 cells that had been treated with either 10 mM VPA or 10 mM PIA, but not 10 mM DA, significantly reduced the Ab-induced synapse damage (Fig. 5A ). This effect of these CM was stimulus specific as they did not affect synapse damage caused by prostaglandin (PG)E 2 (Fig. 5B) . To confirm that these effects of CM were mediated by Ab the CM from VPA and PIAtreated 7PA2 cells were depleted of Ab and mixed with brain extracts containing 2 nM Ab 42 . The protective effect of CM from VPA and PIA-treated cells was removed by Ab depletion, but not by mock-depletion (Fig. 5C ). There were significant correlations between the amounts of synaptophysin and concentrations of Ab 42 monomers in CM from cells treated with VPA or PIA (1.25e10 mM), Pearson's coefficient ¼ 0.94, P < 0.01 (Fig. 5D) .
VPA and PIA and cholesterol synthesis
As VPA has been reported to affect cholesterol metabolism (Kim et al., 2007) the possibility that VPA and PIA reduced cholesterol synthesis was examined. Firstly, the cholesterol concentrations of 7PA2 cells were not significantly altered by treatment with 10 mM VPA or 10 m PIA (Table 2 ). In addition, whereas the effects of the cholesterol synthesis inhibitor squalestatin on 7PA2 cells were reversed by the addition of 5 mM squalene (a non-toxic precursor that is rapidly converted to cholesterol), the inclusion of 5 mM squalene did not alter cholesterol concentrations in VPA or PIAtreated cells. Next we compared the effects of VPA and PIA to those of squalestatin upon the forms of Ab released by treated cells. Although VPA and PIA had a similar effect upon concentrations of Ab 42 oligomers and Ab 42 monomers as squalestatin, the effects of squalestatin, but not those of VPA or PIA, were reversed by the inclusion of squalene (Table 2) . Reports that VPA and PIA reduced the activation of cPLA 2 (Williams and Bate, 2016) and that PLA 2 inhibitors affect the processing of APP (Emmerling et al., 1993) suggest that products of activated cPLA 2 may affect the release of toxic Ab. The activation of cPLA 2 gives rise to the generation of multiple bioactive lipids, including prostaglandins and PAF. Here we tested whether PAF could reverse the effects of VPA or PIA on Ab oligomer formation. CM from 7PA2 cells treated with a combination of 500 nM PAF and 10 mM VPA caused the loss of synaptophysin from neurons (Fig. 6A) .
So did CM from 7PA2 cells mixed with a combination of 500 nM PAF and 10 mM PIA. The addition of PAF also reversed the inhibitory effects of VPA and PIA on the concentrations of Ab 42 oligomers found in CM (Fig. 6B) . The effect of PAF on VPA and PIA-treated cells was dose-dependent; the addition of PAF reversed the VPA and PIAinduced suppression of Ab 42 oligomers (Fig. 6C) and the VPA and PIA-induced increase of Ab 42 monomers (Fig. 6D) .
VPA and PIA altered the distribution of APP in cell membranes
Further studies examined the effects of VPA and PIA upon APP.
Treatment with 10 mM VPA (106 units ± 3.2 compared with 100 units ± 2.6, n ¼ 9, P < 0.01) or 10 mM PIA (106 units ± 3.4 compared with 100 units ± 2.6, n ¼ 9, P < 0.01) caused a small but significant increase in the amounts of APP within cells. Since the processing of APP to toxic Ab peptides is thought to occur within cholesteroldependent micro-domains called lipid rafts we examined whether APP was found in lipid rafts. In control cells approximately 40% of total cellular APP was found within DRMs (lipid rafts) (Fig. 7A) . Significantly less APP was found within DRMs/rafts, and more within the DSMs, in cells treated with 10 mM VPA or 10 mM PIA (Fig. 7A) . Treatment of 7PA2 cells with 10 mM VPA or 10 mM PIA did not affect the amounts of other raft-associated proteins in DRMs including caveolin and the PAF receptor (Fig. 7B) . In cells treated with VPA or PIA (1.25e10 mM) there were significant correlations between the amounts of APP found in lipid rafts and the concentrations of Ab 42 oligomers found in CM (Fig. 7C ). There were also significant inverse correlations between the amounts of APP found in lipid rafts and the concentrations of Ab 42 monomers found in CM (Fig. 7D) . The addition of 500 nM PAF reversed the VPA or PIA- (Selkoe, 2002) control medium (Hardy, 2006) , 10 mM VPA or (Lambert et al., 1998) induced reduction of APP within lipid rafts (Fig. 7E ).
Discussion
VPA, originally used to treat epilepsy, has been proposed to affect the production of Ab and consequently the progression of AD. Here we show that treatment with either VPA or PIA reduced the concentrations of the Ab oligomers in 7PA2 cells and CM. Critically VPA and PIA increased concentrations of Ab monomers.
Firstly, 7PA2 cells were shown to release soluble forms of Ab that have similar toxic properties to the Ab found in soluble brain extracts derived from AD patients. These results are in accordance with prior reports that cell-derived soluble Ab is similar in in size, stability and biological activity to soluble Ab extracted from the brains of AD patients (Walsh et al., 2002; Walsh and Selkoe, 2007) . The major finding of this study was that CM from 7PA2 cells treated with either VPA or PIA did not cause synapse damage. Remarkably, the loss of toxicity of CM from treated cells was accompanied by a relatively small reduction in total Ab concentrations; demonstrating that there was not a simple relationship between the concentrations of Ab in CM and their toxicity. Treatment with VPA or PIA significantly reduced the concentrations of Ab 42 oligomers, the forms of soluble Ab that are closely associated with synapse degeneration and clinical symptoms (Mc Donald et al., 2010) . Furthermore there were significant inverse correlations between the concentrations of Ab 42 oligomers in CM from treated cells and the amounts of synaptic proteins (synaptophysin and CSP) in neurons incubated with such CM.
Treatment of 7PA2 cells with VPA or PIA significantly increased the concentrations of Ab 42 monomers and there were significant inverse correlations between the concentrations of Ab 42 monomers and Ab 42 oligomers in CM. Although Ab monomers and oligomers derived from 7PA2 cells or brain extracts are reported as stable (Shankar et al., 2008; Walsh et al., 2000 Walsh et al., , 2002 Klyubin et al., 2008) the possibility that VPA and PIA caused the dissociation of Ab oligomers was investigated. Direct incubation of VPA or PIA with Ab preparations did not change the amounts of Ab oligomers or Ab monomers indicating that these compounds did not have a direct effect upon Ab oligomers or monomers. This finding suggests that VPA or PIA did not affect oligomerization of Ab monomers in the CM. Either the oligomerization of Ab occurs intracellularly (Walsh et al., 2000) and are released as Ab monomers, dimers and trimers, or Ab monomers are taken up by cells and oligomerized before being re-released.
CM from VPA or PIA-treated cells reduced the Ab oligomerinduced loss of synaptophysin and CSP from neurons. Immunodepletion and filtration studies demonstrated that these effects were mediated by Ab monomers and there were also significant correlations between the concentrations of Ab monomers in CM from treated cells and the amounts of synaptic proteins (synaptophysin and CSP). These observations are consistent with a report that Ab monomers had a neuroprotective role (Giuffrida et al., 2009) . Notably, CM from treated cells did not affect synapse damage induced by PGE 2 indicating that their effects were selective.
VPA has been reported to have multiple effects including inhibition of histone deacetylase which in turn affects neprilysin, an enzyme that affects Ab degradation (Nalivaeva et al., 2012) . However, in this study VPA and PIA had optimal effects at concentrations of 10 mM whereas the inhibition of histone deacetylase required concentrations of 3 mM (Eyal et al., 2005) . Although VPA has also been reported to inhibit cholesterol synthesis (Kim et al., 2007) neither VPA nor PIA significantly altered total cellular cholesterol concentrations. Furthermore, their effects were not reversed by the addition of squalene, a precursor of cholesterol that reversed the effects of cholesterol synthesis inhibitors, indicating that the effects of VPA and PIA upon Ab production were not via inhibition of cholesterol synthesis. We recently showed that VPA and PIA reduced the activation of cPLA 2 (Williams and Bate, 2016) , an enzyme involved for cell signalling and the production of bioactive phospholipids including prostaglandins and PAF (Williams and Bate, 2016; Bosetti et al., 2003) . In this study, PAF, a bioactive phospholipid produced following activation of cPLA 2 , reversed the effects of VPA and PIA upon Ab production, indicating that it was the key mediator involved in this pathway. These results are consistent with the hypothesis that VPA/PIA inhibits cPLA 2 reducing PAF and that PAF affected Ab production.
Observations that the normal intracellular trafficking and endosomal sorting is dysregulated in AD (Toh and Gleeson, 2016) support the theory that endosome/lysosome dysfunction leads to the amyloidgenic processing of APP in endosomal and lysosomal compartments (Nixon, 2017) . Consequently Ab production can be affected by factors that alter the trafficking of APP, b-site APP cleaving enzyme-1 and/or other components of the g-secretase complex. Lipid rafts are a major source of Ab 42 production (Ehehalt et al., 2003) and approximately 40% of APP is found within lipid rafts (DRMs) in these cells. Treatment of cells with either VPA or PIA reduced the amounts of APP within lipid rafts leading to significant correlations between the amounts of APP in lipid rafts and the concentrations of Ab 42 in CM. The positive correlation between amounts of APP in lipid rafts and the concentrations of Ab 42 oligomers suggested that APP in lipid rafts is more likely to be processed into Ab oligomers. Conversely, the negative correlation between the amounts of APP in lipid rafts and the concentrations of Ab 42 monomers suggested that APP resident in the normal cell membrane is more likely to be metabolised to Ab monomers. It should be noted that VPA/PIA did not affect the residency of other lipid raft-associated proteins such as caveolin and the PAF receptor.
The trafficking of APP, and the consequent processing to Ab peptides, is dependent upon multiple factors including membrane composition (Haass et al., 2012) . Proteins found within lipid rafts often traffic via different pathways (Nichols et al., 2001) to proteins found in the normal cell membrane, raising the possibility that APP in lipid rafts traffics to different cell compartments and interacts with different enzymes than APP in the normal cell membrane. Currently we can only speculate that treatment with VPA or PIA alters the trafficking of APP or other components that constitute a mature gsecretase complex. It should be noted that these studies were performed on a non-neuronal cell line that overexpressed APP751. Neuronal cell lines mostly express APP695 (Belyaev et al., 2010) and their expression of other enzymes involved in Ab production may also vary from the 7PA2 cells used here. While it would be unwise to extrapolate results from 7PA2 cells to the clinic these results raise interesting questions concerning APP metabolism that could be investigated further in neuronal cell lines and animal models.
Conclusions
In summary we report that VPA and PIA significantly reduced the amounts of toxic forms of Ab in the CM of 7PA2 cells. The effects of VPA/PIA were twofold; not only did they reduce the concentrations of Ab oligomers, these drugs also increased concentrations of Ab monomers in CM. Critically, CM from treated cells reversed the Ab oligomer-induced synapse damage. These studies suggest that should sufficient concentrations of VPA or PIA penetrate the brain then they may be able to reduce synapse damage in AD. studentship scheme (NC/L001500/1).
